Leão Lima Ronaldo de Souza, De Lorenzo Andrea, Issa Aurora
Cardiovascular Division, Department of Internal Medicine, Universidade Federal do Rio de Janeiro, Rua Rui Vaz Pinto, 220/301, Rio de Janeiro 21931-390, Brazil.
Int J Cardiovasc Imaging. 2008 Jan;24(1):55-9. doi: 10.1007/s10554-007-9225-9. Epub 2007 Apr 12.
Dobutamine (Dob) stress myocardial perfusion scintigraphy (MPS) has been shown to have diagnostic and prognostic value. However, the protocol recommended for Dob-MPS is long and frequently associated with adverse effects. We sought to compare two stress protocols with Dob in patients undergoing MPS.
168 patients undergoing Dob-MPS were consecutively studied. Two protocols were randomly used: progressive doses of Dob (steps of 10 microg/kg/min at 3-min intervals) up to 40 microg/kg/min, aiming at reaching a minimum of 85% of the age-corrected maximal predicted heart rate (HR), possibly adding atropine to maximal Dob dose in case HR was not achieved (conventional protocol) or progressive doses of Dob aiming at the same HR, but adding atropine at the end of the first stage (accelerated protocol). We compared age, gender, coronary risk factors, history of MI or revascularization, Dob infusion and total stress times, maximal HR, percentage of maximal predicted HR, rate-pressure product, ST changes, MPS scores and incidence of adverse effects. In the 84 patients who underwent the accelerated protocol, the incidence of adverse effects was reduced (34.5%) compared to the conventional protocol (54.8%; P < 0.05), as well as Dob infusion duration (508 +/- 130 vs. 715 +/- 142 sec; P < 0.001). We did not observe significant differences between the groups as to age, gender, clinical aspects, maximal HR, percentage of achieved maximal HR, rate-pressure product, ST changes and perfusion scores.
Early administration of atropine makes stress faster and reduces incidence of adverse effects, without reducing efficacy towards achieving the proposed goals.
多巴酚丁胺(Dob)负荷心肌灌注显像(MPS)已被证明具有诊断和预后价值。然而,推荐用于Dob-MPS的方案耗时较长,且常伴有不良反应。我们试图比较在接受MPS检查的患者中两种使用Dob的负荷方案。
连续研究了168例接受Dob-MPS检查的患者。随机采用两种方案:逐渐增加Dob剂量(以每分钟10μg/kg的步长,每隔3分钟递增),直至40μg/kg/min,目标是达到年龄校正后的最大预测心率(HR)的至少85%,如果未达到HR,可能在最大Dob剂量时加用阿托品(传统方案),或逐渐增加Dob剂量以达到相同的HR,但在第一阶段结束时加用阿托品(加速方案)。我们比较了年龄、性别、冠心病危险因素、心肌梗死或血运重建病史、Dob输注时间和总负荷时间、最大HR、最大预测HR的百分比、心率-血压乘积、ST段改变、MPS评分以及不良反应的发生率。在接受加速方案的84例患者中,不良反应的发生率(34.5%)低于传统方案(54.8%;P<0.05),Dob输注持续时间也较短(508±130秒对715±142秒;P<0.001)。在年龄、性别、临床情况、最大HR、达到的最大HR百分比、心率-血压乘积、ST段改变和灌注评分方面,两组之间未观察到显著差异。
早期给予阿托品可使负荷过程更快,并降低不良反应的发生率,同时不降低实现既定目标的疗效。